Posted on January 9th, 2020. Posted by Tom McDonald
Financial markets are notoriously difficult to predict. However, armed with decades of Wall Street experience, our investor relations professionals know what can create a strong IPO market — and what can close that window of opportunity.
As we enter the new year, there are several factors to consider for companies that may be considering an IPO. Based on our experience, here are our predictions for the life sciences IPO market in 2020.
Continue Reading
Posted on December 18th, 2019. Posted by Tom McDonald
Finding out how others view your company can be intimidating, but to make sure your business is headed in the right direction, it’s necessary. A perception audit — an independent investigation into investor and analyst impressions of a company — can help you benchmark your progress over time, identify ways to improve your investor relations plan, and pinpoint any misperceptions in market views. Learn the basics of how to conduct a successful perception audit with this checklist.
Continue Reading
Posted on December 12th, 2019. Posted by Michael Fox
In today’s world of ubiquitous, instantaneous, and interconnected information, integrated communication should be a key strategic priority for all companies. However, it is even more important in the healthcare space, especially for early stage, pre-revenue life sciences companies, where the investor story is indistinguishable from the product or technology story.
Many companies struggle to unify their message and deliver a cohesive story to the marketplace. As a consequence, the many other voices in the arena — competitors, analysts, key opinion leaders, regulators, investors, advocacy groups, the media, and others — shape the perception of your company for you.
Continue Reading
Posted on November 21st, 2019. Posted by Victoria Meissner, M.D.
For publicly traded healthcare companies, clinical trial data and milestone disclosure can present great opportunities as well as significant challenges.
On the path toward regulatory approval, life science and medical device company management will encounter difficult disclosure decisions surrounding clinical and regulatory events. Finding the right balance between the “duty to disclose” vs. “pressure to disclose” dilemma is not easy. If done right, such milestones are a great way to raise visibility within the investment, clinical and scientific communities. If done wrong, the consequences may be severe.
Continue Reading
Posted on November 14th, 2019. Posted by Patti Bank
The decision to host a company research and development (R&D) event for investors and analysts should not be taken lightly. Beyond the associated costs, the amount of time it takes to properly prepare is a big endeavor and can be a significant distraction to a company’s management team. Continue Reading
Posted on October 31st, 2019. Posted by Mark Corbae
Any company, no matter how diligent, can find itself suddenly thrust into a crisis — a natural disaster, product safety issue, whistleblower claim, or other unforeseen emergency. When an incident occurs, especially one that disrupts operations or threatens the company’s reputation, stakeholders, be they customers, shareholders or partners, will want to immediately know what happened and how they’re affected. Mishandling the crisis can exacerbate the problem and shake public trust, causing long-lasting harm. And in the current era of instantaneous digital and social media communications, if you don’t communicate during an urgent situation, others may get there first and define it for you.
Continue Reading
Posted on October 23rd, 2019. Posted by Terri Clevenger
As the rock ‘n’ roll generation begins settling into their senior years, the “Baby Boomer factor” is wielding its heavy influence on healthcare as it has on other industries. Healthcare spending has grown substantially over the past few decades, and demand will likely remain strong as the number of Americans aged 65 and older will more than double by 2060. At the same time, technologies such as artificial intelligence, blockchain, software-as-a-medical-device and other advances are transforming the healthcare industry and threatening the status quo through rich networks of connection, collaboration, and interdependence.
Continue Reading
Posted on October 2nd, 2019. Posted by Tim Kane
Creating a presentation for an audience of investors is a balancing act. On the one hand, there are specific pieces of information that investors want to see in a certain way, and if you don’t provide that information, they’ll wonder what you’re trying to hide. On the other hand, investors see so many presentations every month — hundreds of slides, thousands of charts, and an endless barrage of bullets and sub-bullets — it’s no wonder that so few make a lasting impression.
Continue Reading
Posted on September 24th, 2019. Posted by Jack Powell
Face-to-face meetings with key members of the institutional investor community can be critical to your company’s success in the public markets. However, it can often be challenging for companies to reach the right institutional accounts and appropriately balance these IR activities with the many other demands on management’s time.
Continue Reading
Posted on September 12th, 2019. Posted by Tom McDonald
Earnings calls are your opportunity to communicate your company’s story to the world. These calls give analysts and investors insight into the progress you’re making on financial metrics and clues about future performance. It’s critical to make these calls count.
Continue Reading
